MCC Publications

2021

A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy. Fischer N, Seo EJ, Abdelfatah S, Fleischer E, Klinger A, Efferth T. Invest New Drugs. 2021 Jan 25. Online ahead of print.

AMG900 as novel inhibitor of the translationally controlled tumor protein. Fischer N, Seo EJ, Klinger A, Fleischer E, Efferth T. Chem Biol Interact. 2021 Jan 25;334:109349.

2020

Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma. Özenver N, Abdelfatah S, Klinger A, Fleischer E, Efferth T. Invest New Drugs. 2020 Sep 25. Online ahead of print.

Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells. Dawood M, Hegazy MF, Elbadawi M, Fleischer E, Klinger A, Bringmann G, Kuntner C, Shan L, Efferth T. Biochem Pharmacol. 2020 Oct;180:114176.

Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells. Özenver N, Dawood M, Fleischer E, Klinger A, Efferth T. Molecules. 2020 Jul 15;25(14):3224.

Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344. Dawood M, Fleischer E, Klinger A, Bringmann G, Shan L, Efferth T. Pharmacol Res. 2020 Oct;160:105076.

Putative molecular determinants mediating sensitivity or resistance towards carnosic acid tumor cell responses. Mahmoud N, Saeed MEM, Sugimoto Y, Klinger A, Fleischer E, Efferth T. Phytomedicine. 2020 Oct;77:153271.

Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells. Abdelfatah S, Böckers M, Asensio M, Kadioglu O, Klinger A, Fleischer E, Efferth T. Phytomedicine. 2020 Mar 10:153196.

Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells. Hegazy MF, Fukaya M, Dawood M, Yan G, Klinger A, Fleischer E, Zaglool AW, Efferth T. Invest New Drugs. 2020 Jun;38(3):650-661.

Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Abdelfatah S, Fleischer E, Klinger A, Wong VKW, Efferth T. Invest New Drugs. 2020 Feb;38(1):1-9.

How to design selective ligands for highly conserved binding sites: A case study using N-myristoyltransferases as model system C Kersten, E Fleischer, J Kehrein, C Borek, E Jaenicke, C Sotriffer, R Brenk. J Med Chem. 2020 Mar 12;63(5):2095-2113

2019

Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5. Sachs J, Döhl K, Weber A, Bonus M, Ehlers F, Fleischer E, Klinger A, Gohlke H, Pietruszka J, Schmitt L, Teusch N. Front Pharmacol. 2019 Apr 16;10:400.

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Abdelfatah S, Berg A, Huang Q, Yang LJ, Hamdoun S, Klinger A, Greten HJ, Fleischer E, Berg T, Wong VKW, Efferth T. Acta Pharm Sin B. 2019 Sep;9(5):1021-1034.

Former

Lawsone derivatives target the Wnt/beta-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Hamdoun S, Fleischer E, Klinger A, Efferth T. Biochem Pharmacol. 2017 Dec 15;146:63-73.

Inhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole Resistance. Keniya MV, Fleischer E, Klinger A, Cannon RD, Monk BC. PLoS One. 2015 May 7;10(5):e0126350.

Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach Schroeder J., Klinger A., Oellien F., Marhöfer R.J., Duszenko M., Selzer PM. J Med Chem. 2013; 56(4),1478-90.



Highest Quality and Competitive Price-Performance Ratio!

  • We supply high-quality compounds and services, both at world-wide competitive prices.
  • Our quality is based on competence and experience obtained from many years being in industrial pharmaceutical and agrochemical research.
  • All our compounds are provided with HPLC-MS / H-NMR analytics as standard feature.
  • Confidentiality on all projects is taken for granted.